20th-22nd March

London, UK

Download Brochure

Morning Workshop
Tuesday March 20th, 2018

09.00 - 12.00

Optimising Complement-based Clinical Trial Design for Expansion Beyond Ultra-Rare Diseases


Workshop Leader: Eva-Maria Nichols, Head of Complement, GlaxoSmithKline Workshop Leader: Kiran Nistala, Experimental Medicine Physician , GlaxoSmithKline

A number of factors in complement pathway research present barriers to producing high quality data, creating uncertainty regarding the true efficacy and safety of new therapies.

This workshop will discuss the following:

  • Collecting and handling samples to avoid ex-vivo activation and improve data quality
  • Advancing patient recruitment and stratification to streamline trials
  • Determining the most effective clinical endpoints
  • Overcoming issues surrounding dosing during trials

Leave this workshop having explored the various strategies you can implement to improve the key aspects of clinical trial design.

Eva-Maria Nichols, Head of Complement, GlaxoSmithKline

Kiran Nistala, Experimental Medicine Physician , GlaxoSmithKline

Afternoon Workshop
Tuesday March 20th, 2018

13.00 - 16.00

Recognising the Potential of Complement in Neurodegeneration: From the Fundamental Science to Clinical Development


Workshop Leader: Paul Morgan, Professor of Immunology and Director, Systems Immunity Research Institute, Cardiff University Workshop Leader: Frank Baas, CSO, Complement Pharma

In the past few years, neurodegeneration has been identified as one of the most promising new avenues for complement therapeutics, but collaboration from the academic and industry leaders is needed to advance the development of this approach.
This workshop will discuss the following:

  • Looking at complement as a more proximal factor in the demise of neurons and synapses
  • Analysing the available data to explore the potential of complement-based drugs in this area
  • Overcoming potential pitfalls with this approach, specific to individual neurodegenerative diseases and approaches for complement inhibition
  • Examining the key safety concerns associated with the use of complement-based drugs in this context

Leave this workshop having thoroughly explored the potential for complement-based drugs to treat neurodegenerative diseases.

Paul Morgan, Professor of Immunology and Director, Systems Immunity Research Institute, Cardiff University

Frank Baas, CSO, Complement Pharma